# KLN-1010

Source: https://onco.cc/drugs/kln-1010/  
OnCo record `kln-1010` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

KLN-1010 is an experimental in vivo CAR-T gene therapy from Kelonia Therapeutics, in phase 1 trials for relapsed and refractory multiple myeloma.

## Summary

KLN-1010 is an in vivo CAR-T gene therapy (lentiviral-based iGPS particles, one-time intravenous dose) from Kelonia Therapeutics, with Eli Lilly and Company as acquirer. A one-time intravenous gene therapy whose engineered lentiviral particles enter T cells inside the body so that the patient's own cells make CAR-T cells against BCMA (B cell maturation antigen), as the registry's study title states; no cell collection or manufacturing is needed. Its furthest stage is phase 1, for relapsed and refractory multiple myeloma. ClinicalTrials.gov registers it in one study linked below. Phase 1 inMMyCAR open and enrolling (NCT07075185). Eli Lilly agreed to acquire Kelonia (announced 20 April 2026; up to $7.00 billion); site now says 'A wholly owned subsidiary of Eli Lilly and Company'. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: KLN-1010
- Modality: In vivo CAR-T gene therapy (lentiviral-based iGPS particles, one-time intravenous dose)
- Mechanism: A one-time intravenous gene therapy whose engineered lentiviral particles enter T cells inside the body so that the patient's own cells make CAR-T cells against BCMA (B cell maturation antigen), as the registry's study title states; no cell collection or manufacturing is needed.

## Sources

- Kelonia Therapeutics: keloniatx.com: https://keloniatx.com/pipeline/
- Kelonia Therapeutics: pharmalive.com: https://www.pharmalive.com/lilly-to-acquire-kelonia-therapeutics-to-advance-in-vivo-car-t-cell-therapies/
- Kelonia Therapeutics: keloniatx.com: https://keloniatx.com/
- Kelonia Therapeutics: clinicaltrials.gov: https://clinicaltrials.gov/study/NCT07075185
- ClinicalTrials.gov: trials of KLN-1010: https://clinicaltrials.gov/search?intr=KLN-1010

## Connected records

- cancers: [Relapsed or refractory multiple myeloma](https://onco.cc/cancers/myeloma-relapsed-refractory/)
- targets: [BCMA](https://onco.cc/targets/bcma/)
- companies: [Kelonia Therapeutics](https://onco.cc/companies/kelonia-therapeutics/)
- trials: [A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma](https://onco.cc/trials/nct07075185/)

---
JSON: https://onco.cc/api/v1/entities/kln-1010.json